Related references
Note: Only part of the references are listed.Churg-Strauss syndrome associated with montelukast therapy
N. Girszyn et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2008)
Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production
R. J. Pepper et al.
RHEUMATOLOGY (2008)
Lntravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality
L. G. Goransson et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2008)
The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case crossover study
T. Hauser et al.
THORAX (2008)
The potential utility of B cell-directed biologic therapy in autoimmune diseases
D. G. Arkfeld
RHEUMATOLOGY INTERNATIONAL (2008)
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis - Remission, relapse, and re-treatment
K. G. C. Smith et al.
ARTHRITIS AND RHEUMATISM (2006)
Share Paper
